ReviewHematology. American Society of Hematology. Education Program2024
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment.
Review in Hematology. American Society of Hematology. Education Program, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- ASSIST: Refinement of a Benefits Navigator Intervention Among Low-Income Pediatric Oncology Families.Pediatric blood & cancer · 2026Article
- Pediatric Oncology Clinical Trial Participation Among Families From Historically Marginalized Groups.JAMA network open · 2026Article
- Prevalence and Trajectory of Household Material Hardship Among Children With Advanced Cancer.Pediatric blood & cancer · 2026Article
- Pediatric RISE: Development of a Poverty-Targeted Cash Support Intervention for Pediatric Cancer.Pediatric blood & cancer · 2026Article
- Delivering Care Consistent With the Psychosocial Standards-Provider Report: Implementing the Standards Together-Engaging Parents and Providers in Psychosocial Care (iSTEPPP) Study.Pediatric blood & cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Racial, ethnic, and socioeconomic survival disparities have been well-demonstrated across population-based and clinical trial datasets in pediatric hematologic malignancies. To date, these analyses have relied on trial-collected data such as race, ethnicity, insurance, and zip code. These exposures serve as proxies for factors such as structural racism, genetic ancestry, and adverse social determinants of health (SDOH). Systematic measurement of SDOH and social needs-and interventions targeting these needs-are feasible in pediatric oncology. We use these data to present a roadmap for the next decade of health equity research to identify actionable mechanisms and develop a portfolio of interventions to advance equitable outcomes across pediatric hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.